Navigation Links
Beike Biotechnology Study Suggests Adult Stem Cells Show Promise,for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood can potentially improve the quality of life for patients whose lower extremities are affected by peripheral vascular disease, according to a study in China.

SHENZHEN, China, July 02, 2007 /PRNewswire/ -- Beike Biotechnology Co., Ltd. (http://www.beikebiotech.com) today announced that a team led by Dr. Yang Xiaofeng at its collaborating hospital in Shenyang completed a study to assess clinical efficacy, safety, and feasibility of transplantation of peripheral blood stem cells for patients with peripheral vascular disease of the lower extremities.

Beike is best known for its research and treatments for ataxia, cerebral palsy, spinal cord injury and MS which are often covered by China Stem Cell News (http://www.stemcellschina.com), a leading stem cell news site. However, Beike also has broad experience in research and treating vascular diseases with adult stem cells mostly through its collaboration with Shenyang 463 hospital.

A total of 152 patients with peripheral vascular disease of the lower extremities were enrolled into this non-controlled study from November 2003 to March 2006. The results were published in the Journal of Geriatric Cardiology which publishes original peer-reviewed clinical and experimental reports on all aspects of cardiovascular disease in the elderly.

A second study was completed during the same period comparing the relative improvement of lower limb ischemia (lack of blood supply) between transplantation of autologous peripheral blood stem cells and transplantation of bone marrow stem cells. The study is awaiting publication in a peer- reviewed journal.

At 12 weeks, primary symptoms, including lower limb pain and coldness, were significantly improved in 137 (90.1%) of the patients; limb ul
'"/>




Page: 1 2 3

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
3. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
4. Prana Biotechnology Presents New Key Findings on PBT2
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
6. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
7. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
8. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
11. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  Decision Resources Group ... infectious disease (ID) specialists are willing to prescribe ... (oritavancin) for use as OPAT, approximately two-thirds of ... agents to their hospital inpatients. However, our findings ... patients are initiated on OPAT following hospital discharge, ...
(Date:7/10/2014)... Decision Resources Group finds that over half ... and Drug Administration,s (FDA) approval of Vifor Fresenius Medical ... approved by the FDA in November 2013 for the ... on dialysis. Other key findings from the ... : , Bundling: ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
... Varian Medical Systems (NYSE: VAR ) ... U.S. Customs and Border Protection (CBP) for multiple IntellX® cargo ... company,s largest single order for Varian,s IntellX gantry systems. The ... vehicles for both border security and manifest verification purposes. ...
... 2011 DURECT Corporation (Nasdaq: DRRX ) ... (FDA) has accepted the resubmission of the New Drug ... KG ) and the PDUFA goal date ... ) REMOXY, based on DURECT,s ORADUR® technology, ...
Cached Medicine Technology:Varian Medical Systems' Security and Inspection Products Group Receives Largest Single Order for IntellX Systems 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 2REMOXY® New Drug Application Accepted by the FDA with PDUFA Goal Date of June 23, 2011 3
(Date:7/11/2014)... 12, 2014 According to new ... market is expected to register a CAGR of ... Browse 71 market data tables and 76 figures ... "C4ISR Market"., http://www.marketsandmarkets.com/Market-Reports/c4isr-market-1315.html , Early buyers ... http://www.marketsandmarkets.com/requestCustomization.asp?id=1315 , The report provides market analysis ...
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- People with the lowest ... called peripheral artery disease (PAD), a new study suggests. ... blood to the limbs, most often the legs. The condition ... of the arteries throughout the body. People with PAD have ... analyzed data from nearly 6,800 people with PAD who took ...
(Date:7/11/2014)... 11, 2014 The report, “Specialty ... Applications & Geography - 2018,” defines and segments ... with an analysis and forecast of the volumes ... fibers (Para aramids, meta aramids, UHMW Polyethylene, carbon ... PPS fiber, PBI fiber, PBO fiber, and liquid ...
(Date:7/11/2014)... -- In people with sex addiction, pornography affects the ... in drug addicts as they consume drugs, a new ... activity between patients who have compulsive sexual behavior and ... study author Dr. Valerie Voon, of the University of ... Voon,s research involved 19 men with sex addiction ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, Inc. ... to cell and gene therapies for cancer – ... organization as Senior Development Officer. , Corday is ... gifts and addressing influential donors. Prior to joining ... NewYork Presbyterian Hospital/Columbia University Medical Center, where he ...
Breaking Medicine News(10 mins):Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 2Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 3Health News:C4ISR Market Estimated to Reach $93.04 Billion by 2019 - New Report by MarketsandMarkets 4Health News:Poor More Prone to Leg Circulation Trouble 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 2Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 3Health News:Specialty Synthetic Fibers & Glass Fiber Market Poised to Reach $20.1 Billion at a CAGR of 5.2% by 2018 – Report by MarketsandMarkets 4Health News:Brains of Sex Addicts May Be Wired Like Those of Drug Addicts, Study Finds 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... , , , ... females, a team of Ohio physicians representing the Women,s Dermatologic ... safety education for tennis fans enjoying the Western & Southern ... Saturday, August 15, from 9:00 a.m.-5:00 p.m. Led by board-certified dermatologist ...
... 10 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, ... multi-year distribution,agreements for China with Biotest AG and Cutera ... in Dreieich, Germany (SDAX: BIO3), specializes in,innovative hematology and ...
... , , ANN ARBOR, Mich., ... U.S. health systems based on their hospitals, clinical performance. They are: , , ... , Catholic Healthcare Partners -- Cincinnati, OH , ... HealthEast Care System -- Saint Paul, MN , Henry ...
... PHILADELPHIA, Pennsylvania, August 10 , ... Improve Patient Care, Help,Prevent Costly Mistakes; Hospitals Benefit From ... a world leader in healthcare and medical publishing and ... tool within,Mosby,s Nursing Consult designed to help nurses prevent ...
... ... Enhances Innovative Solutions for Travelers and Individuals , ... Indianapolis, IN (PRWEB) August 10, 2009 ... insurance, today announced it has signed an agreement with Eldorado Computing, Inc. (Eldorado) ...
... ... balance, confidence and quality of life. , ... Hamilton, AL (PRWEB) Jeanne Crace, 70, who has five daughters, ... Parkinson,s disease. , , , , ,Parkinson,s Disease remains a mystery of medical ...
Cached Medicine News:Health News:Ohio Dermatologists to Help Tennis Community Get Into the Swing of Sun Safety 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 2Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 3Health News:Chindex International Announces Exclusive Distribution Agreements in China for Leading Clinical Chemistry and Aesthetic Laser Products 4Health News:Thomson Reuters Research Identifies Top U.S. Health Systems 2Health News:Thomson Reuters Research Identifies Top U.S. Health Systems 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 2Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 3Health News:Nurses to Benefit From New CMS Never Events Resource Area on Mosby's Nursing Consult 4Health News:HCC Medical Insurance Services Selects Eldorado's Innovative Claims & Benefits Platform 2Health News:Exploring Newly Found Freedom with the GaitAid for Parkinson's Disease 2Health News:Exploring Newly Found Freedom with the GaitAid for Parkinson's Disease 3
They employ Lea Symbols. Contrast levels are the same at 25%, 10%, 5%, 2.5% and 1.25%. Each offers a different set of Lea Symbols to guard against memorization. Also uses recording forms (P/N 215400)...
Symbol 10' Test Chart 10/100 to 10/10 size. 9" x 14"....
Wilbrandt-binkhorst irrigating cannula....
Binkhorst, length 35 mm....
Medicine Products: